EUVIMEDEUVIMED entdecken
Open Access

Novel RORγt inverse agonists limit IL-17-mediated liver inflammation and fibrosis

Afrooz Dabbaghizadeh, Jessica Dion, Yousef Maali, Ahmed Fouda iD, Nathalie Bédard, Gertruda Evaristo iD, Ghada S Hassan, Jean Tchervenkov, Naglaa H Shoukry iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Afrooz Dabbaghizadeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada. Hauptthemen laut MEDLINE: Interleukin-17, Nuclear Receptor Subfamily 1, Group F, Member 3, Liver Cirrhosis, Thiophenes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a global health problem. IL-17A has proven profibrogenic properties in liver disease making it an interesting therapeutic target. IL-17A is regulated by RORγt and produced by Th17 CD4+ and γδ-T cells. We hypothesized that blocking IL-17A production will limit fibrosis progression by reducing recruitment of inflammatory cells. Herein, we tested the therapeutic potential of 2 novel RORγt inverse agonists (2,3 derivatives of 4,5,6,7-tetrahydro-benzothiophene) in a mouse model of CCl4-induced liver injury. C57BL/6 mice received 2 weekly injections of CCl4 for 4 weeks. As of week 3, mice were treated with the 2 novel inverse agonists (TF-S10 and TF-S14) and GSK805 as a positive control. Mice treated with the inverse agonists showed reduced immune cells infiltrate around the portal and central veins. TF-S14 significantly reduced AST levels (P < 0.05), and all inhibitors led to an improvement in relative liver weight (liver index). Flow cytometry analysis demonstrated that all inhibitors reduced the numbers of intrahepatic lymphocytes (CD4+, CD8+, and γδ-T cells, P < 0.05), and myeloid (CD11b+) cells (P = 0.04), most significantly eosinophils (P < 0.05). Furthermore, IL-17A production by CD4+ and γδ-T cells was diminished (P < 0.05 and P < 0. 01, respectively). Finally, livers from inhibitors-treated mice showed decreased markers of hepatic stellate cell activation (desmin and ɑ-smooth muscle actin [ɑ-SMA]) and significantly reduced expression of the profibrogenic genes (Col1a1, Acta, Loxl2, and Tgfβ) (P < 0.001). This was accompanied by diminished collagen deposition as measured by Picrosirius Red staining (P < 0.001). In conclusion, our results suggest that inhibition of the IL-17A pathway could be a promising therapeutic strategy for liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-17Nuclear Receptor Subfamily 1, Group F, Member 3Liver CirrhosisThiophenesAnimalsMiceMice, Inbred C57BLMaleLiverCarbon TetrachlorideHepatic Stellate CellsTh17 CellsInflammationDisease Models, AnimalChemical and Drug Induced Liver InjuryDrug Inverse Agonism

Stichwörter der Autor:innen

IL-17ARORγtinflammationinverse agonistliver fibrosis

Substanzen

Interleukin-17Nuclear Receptor Subfamily 1, Group F, Member 3Carbon TetrachlorideThiophenesIl17a protein, mouse

Autor:innen und Institutionen

  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
  • Département de Microbiologie, Infectiologie et Immunologie, Faculté de médecine, Université de Montréal, Montréal, QC, Canada.
  • Division of Surgical and Interventional Science, Department of Surgery, McGill University, Montreal, QC, Canada.
  • Division of General Surgery, Section of Transplant Surgery, Department of Surgery, McGill University, Montreal, QC, Canada.
  • Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • McGill University Health Centre, Montréal, QC, Canada.

ORCID-Profile: Ahmed Fouda, Gertruda Evaristo, Naglaa H Shoukry

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Dabbaghizadeh, A., Dion, J., Maali, Y., Fouda, A., Bédard, N., Evaristo, G., Hassan, G. S., Tchervenkov, J., & Shoukry, N. H. (2025). Novel RORγt inverse agonists limit IL-17-mediated liver inflammation and fibrosis. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf014

Vancouver

Dabbaghizadeh A, Dion J, Maali Y, Fouda A, Bédard N, Evaristo G, et al. Novel RORγt inverse agonists limit IL-17-mediated liver inflammation and fibrosis. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf014

BibTeX
@article{Dabbaghizadeh2025,
  author = {Dabbaghizadeh, Afrooz and Dion, Jessica and Maali, Yousef and Fouda, Ahmed and Bédard, Nathalie and Evaristo, Gertruda and Hassan, Ghada S and Tchervenkov, Jean and Shoukry, Naglaa H},
  title = {Novel RORγt inverse agonists limit IL-17-mediated liver inflammation and fibrosis},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf014}
}
Kostenlos starten →